Fig. 2
From: Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv
Binding of TfRscFv-liposomes to tumor cells. The human head and neck cancer JSQ-3 cells (a1) and prostate cancer DU145 cells (a2) were incubated with TfRscFv-LipA1, TfRscFv-LipA2, free TfRscFv, non-targeted liposomes (LipA) or FITC-labled human transferrin (Tf-FITC). After immunofluorescent staining with anti-c-Myc antibody followed with FITC-labeled sheep-anti-mouse IgG antibody, the cells were analyzed by flow cytometery. UT: untreated control cells. TfRscFv-LipA1 and TfRscFv-LipA2 binds to tumor cells comparable to that observed with human transferrin. The stained cells were also observed under a fluorescence microscope. (b1), (c1) and (d1) are TfRscFv-LipA2-treated JSQ-3 cells observed with FITC filter, the green fluorescence indicates the presence of TfRscFv. (b2), (c2) and (d2) are the corresponding fields observed with rhodamine filter, the red fluorescence indicates the presence of liposomes.